Protein interactions at the carboxyl terminus of p53 result in the induction of its in vitro transactivation potential

被引:47
作者
Mundt, M
Hupp, T
Fritsche, M
Merkle, C
Hansen, S
Lane, D
Groner, B
机构
[1] INST EXPT CANC RES, TUMOR BIOL CTR, D-79106 FREIBURG, GERMANY
[2] UNIV DUNDEE, DEPT PATHOL, NINEWELLS HOSP & MED SCH, DUNDEE DD1 4HN, SCOTLAND
[3] UNIV DUNDEE, DEPT BIOCHEM, CANC RES CAMPAIGN LABS, DUNDEE DD1 4HN, SCOTLAND
关键词
p53; phosphorylation; allosteric activation; in vitro transcription; specific DNA binding; latent and activated p53;
D O I
10.1038/sj.onc.1201174
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The tumor suppressor protein p53 is a transcription factor frequently inactivated in human cancers. We have studied the DNA binding potential and the transcriptional activity of p53 variants and p53 protein complexes in in vitro transcription assays, p53 specific transcription was measured via introduction of radioactive UTP into G-free cassette transcripts regulated by promoter sequences containing p53 response elements. Latent and activated p53 fractions were prepared from insect cells infected with p53 encoding baculoviruses by chromatography on heparin columns, p53 fractions distinguishable by their specifc DNA binding activities and their recognition by monoclonal antibody PAb421 were obtained. Specific DNA binding and binding to PAb421 are mutually exclusive. The C-terminus of p53 can be phosphorylated by casein kinase II, protein kinase C and cyclin dependent kinases. The antibody PAb421 binds within the PKC phosphorylation site of p53 and is able to activate DNA binding of latent p53 in vitro. Activation of p53 by PAb421 also results in enhanced transactivation in vitro. Dephosphorylation of latent p53 with phosphatase 2A does not change these properties. This suggests that a conformational change in the carboxyl terminal domain of p53 controls the transactivation potential of p53.
引用
收藏
页码:237 / 244
页数:8
相关论文
共 43 条
[1]  
ABARZUA P, 1995, CANCER RES, V55, P3490
[2]  
ADDISON C, 1990, ONCOGENE, V5, P423
[3]   P53 BINDS SINGLE-STRANDED-DNA ENDS AND CATALYZES DNA RENATURATION AND STRAND TRANSFER [J].
BAKALKIN, G ;
YAKOVLEVA, T ;
SELIVANOVA, G ;
MAGNUSSON, KP ;
SZEKELY, L ;
KISELEVA, E ;
KLEIN, G ;
TERENIUS, L ;
WIMAN, KG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (01) :413-417
[4]   A PROTEOLYTIC FRAGMENT FROM THE CENTRAL REGION OF P53 HAS MARKED SEQUENCE-SPECIFIC DNA-BINDING ACTIVITY WHEN GENERATED FROM WILD-TYPE BUT NOT FROM ONCOGENIC MUTANT P53-PROTEIN [J].
BARGONETTI, J ;
MANFREDI, JJ ;
CHEN, XB ;
MARSHAK, DR ;
PRIVES, C .
GENES & DEVELOPMENT, 1993, 7 (12B) :2565-2574
[5]   CHARACTERIZATION OF THE TUMOR SUPPRESSOR PROTEIN-P53 AS A PROTEIN-KINASE-C SUBSTRATE AND A S100B-BINDING PROTEIN [J].
BAUDIER, J ;
DELPHIN, C ;
GRUNWALD, D ;
KHOCHBIN, S ;
LAWRENCE, JJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1992, 89 (23) :11627-11631
[6]   THE CARBOXYL-TERMINAL DOMAIN OF THE P53 PROTEIN REGULATES SEQUENCE-SPECIFIC DNA-BINDING THROUGH ITS NONSPECIFIC NUCLEIC ACID-BINDING ACTIVITY [J].
BAYLE, JH ;
ELENBAAS, B ;
LEVINE, AJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (12) :5729-5733
[7]   CHARACTERIZATION OF BACULOVIRUS RECOMBINANT WILD-TYPE P53 - DIMERIZATION OF P53 IS REQUIRED FOR HIGH-AFFINITY DNA-BINDING AND CYSTEINE OXIDATION INHIBITS P53 DNA-BINDING [J].
DELPHIN, C ;
CAHEN, P ;
LAWRENCE, JJ ;
BAUDIER, J .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1994, 223 (02) :683-692
[8]  
FRITSCHE M, 1993, ONCOGENE, V8, P307
[9]  
FUCHS B, 1995, ONCOGENE, V10, P789
[10]   TISSUE-SPECIFIC INVITRO TRANSCRIPTION FROM THE MOUSE ALBUMIN PROMOTER [J].
GORSKI, K ;
CARNEIRO, M ;
SCHIBLER, U .
CELL, 1986, 47 (05) :767-776